10.1038/s41598-021-97967-0 Summary Keywords heart failure, GLP-1, glucagon-like peptide-1, clinical trials, cardiovascular disease, cardiovascular outcome studies, diabetes, obesity Citation Kreiner FF, Hovingh GKK and von Scholten BJ (2022) The potential of glucagon-like peptide-1 receptor agonists in heart failure
GLP-1 Drugs Drop More Than Just Weight October 19, 2023 The S&P 500 Index (+13.9% year-to-date) and the Nasdaq Composite (+29.7% year-to-date) have performed well so far in 2023, fueled by optimism surrounding artificial intelligence (AI), declining inflation and the economys resilience in the face of rising interest rates
Tools for tracking and optimizing your timing Optimization requires measurement
The GLP-1-RA group was associated with reduction in acetazolamide dosage at M6 (\(\beta\)= 288.15, 95% CI 553.09, 23.22, p = 0.03), which did not withstand the adjustment for weight loss
Glucagon-like-peptide-2 (GLP-2) is a similar compound that is typically not considered an incretin due to its lack of glycemic effects
